

### STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2005 VERMONT

#### LIST OF TABLES

#### OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

### FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

#### FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY

TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND

BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT. BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND

THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY

BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH,

BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES

AMONG NONDUALS

#### FOR DUAL ELIGIBLE BENEFICIARIES

TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BRAND STATUS AND

BENEFICIARY CHARACTERISTIC

TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS. BY BENEFICIARY CHARACTERISTIC

TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS. BY BRAND STATUS AND

THERAPEUTIC CATEGORY

TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

BY TOP 10 DRUG GROUP

TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS. BY BENEFICIARY CHARACTERISTIC

TABLE D.12, USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY

BENEFICIARY CHARACTERISTIC

TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

#### SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74 SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL

ELIGIBLE BENEFICIARIES

TABLE ND.2 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY  $^{a,\ b}$ NONDUAL BENEFICIARIES, VERMONT, 2005

		١	Number of	Beneficia	ries			N	umber of B	enefit Mon	ths	
Beneficiary						Other/						Other/
Characteristics	All	Aged	Disabled	Adults	Children	Unknown	All	Aged	Disabled	Adults	Children	Unknown
All	126,454	278	9,117	49,443	67,516	100	1,187,862	2,547	101,325	420,132	663,025	833
Age												
5 and younger	22,612	0	351	0	22,261	0	214,363	0	3,869	0	210,494	0
6-14	31,853	1	1,345	1	30,506	0	328,438	12	15,369	5	313,052	0
15-20	17,630	0	1,206	2,078	14,343	3	165,768	0	13,617	15,950	136,186	15
21-44	38,707	0	2,854	35,401	400	52	330,978	0	31,636	295,713	3,221	408
45-64	15,212	3	3,300	11,860	5	44	144,229	36	36,180	107,545	60	408
65-74	221	85	50	85	0	1	2,065	782	522	759	0	2
75-84	127	101	9	16	1	0	1,180	921	108	139	12	0
85 and older	92	88	2	2	0	0	841	796	24	21	0	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Gender												
Female	68,603	160	4,788	30,240	33,315	100	651,930	1,482	53,578	268,496	327,541	833
Male	57,851	118	4,329	19,203	34,201	0	535,932	1,065	47,747	151,636	335,484	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Race												
White	72,333	142	7,025	33,157	31,957	52	700,429	1,290	78,900	289,574	330,240	425
African American	1,474	3	87	633	751	0	13,764	36	948	5,307	7,473	0
Other/unknown	52,647	133	2,005	15,653	34,808	48	473,669	1,221	21,477	125,251	325,312	408
Use of Nursing Facilities <sup>c</sup>												
Entire year	87	33	53	0	0	1	844	302	541	0	0	1
Part year	132	12	101	19	0	0	1,368	133	1,064	171	0	0
None	126,235	233	8,963	49,424	67,516	99	1,185,650	2,112	99,720	419,961	663,025	832
Maintenance Assistance Statu	s											
Cash	20,192	31	7,719	3,990	8,452	0	213,130	341	87,546	39,126	86,117	0
Medically needy	8,588	116	578	5,557	2,337	0	75,110	1,028	5,264	50,340	18,478	0
Poverty-related	49,405	0	0	2,532	46,773	100	473,322	0	0	17,874	454,615	833
Other/unknown	48,269	131	820	37,364	9,954	0	426,300	1,178	8,515	312,792	103,815	0
Managed Care (MC) Status				,	,		,	,		, -	,	
Fee-for-service (FFS) all year	126,454	278	9,117	49,443	67,516	100	1,187,862	2,547	101,325	420,132	663,025	833
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0

a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3 ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC<sup>a, b</sup> NONDUAL BENEFICIARIES, VERMONT, 2005

Beneficiary	Percentage with	Mean Number	Mara Durch	Ф D	Mean \$, All Medicaid	Rx \$ as a Percentage of All Medicaid	Number of
Characteristics	at Least One Rx 67.6	of Rx 9.3	Mean Rx \$			FFS \$ <sup>d</sup>	Beneficiaries 426 454
AII	67.6	9.3	\$622	\$67	\$3,841	10.2	126,454
Age	07.0	2.2	450	40	0.040	7.0	00.040
5 and younger	67.6	3.3	159	48	,	7.8	22,612
6-14	60.8	4.5	341	77	,	9.5	31,853
15-20	64.5	6.4	457	72	,	9.0	17,630
21-44	70.5	11.5	732	64	,	20.0	38,707
45-64	78.0	25.6	1,775	69	5,970	29.7	15,212
65-74	74.2	28.7	1,719	60	,	28.5	221
75-84	70.1	28.2	1,739	62	,	24.2	127
85 and older	63.0	32.3	1,745	54	,	11.3	92
Unknown	0.0	0.0	0	0	0	0.0	0
Basis of Eligibilitye							
Aged	64.0	31.6	1,818	58	10,362	17.5	278
Disabled	86.3	37.1	3,009	81	18,820	16.0	9,117
Adults	70.5	11.3	690	61	2,824	24.4	49,443
Children	62.9	4.0	244	62	2,532	9.6	67,516
Unknown	74.0	11.9	712	60	7,378	9.6	100
Gender							
Female	71.9	10.9	674	62	3,700	18.2	68,603
Male	62.4	7.4	560	75	4,009	14.0	57,851
Unknown	0.0	0.0	0	0	0	0.0	0
Race							
White	73.2	12.3	816	67	4,677	17.5	72,333
African American	65.3	6.4	444	70	3,354	13.2	1,474
Other/unknown	59.9	5.3	359	68	2,707	13.3	52,647
Use of Nursing Fac	ilities <sup>f</sup>						
Entire year	95.4	96.0	6,542	68	58,576	11.2	87
Part year	99.2	89.9	5,727	64	59,385	9.6	132
None	67.5	9.1	612	67	3,745	16.3	126,235
Maintenance Assist	tance Status						
Cash	78.6	19.8	1,485	75	9,045	16.4	20,192
Medically needy	70.0	11.2	688	62	3,564	19.3	8,588
Poverty related	61.1	3.4	189	56	1,719	11.0	49,405
Other/unknown	69.1	10.6	692	65	3,886	17.8	48,269

a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving fost care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC<sup>a, b</sup> NONDUAL BENEFICIARIES, VERMONT, 2005

					Nur	mber of Rx, F	Percentage w	/ith:			Numb	er
Beneficiary Characteristics	Mean Number of Rx	Mean Rx \$	Rx \$ as a Percentage of All Medicaid FFS \$ <sup>c</sup>	None		More than 1, but 2 or Less	More than 2, but 5 or Less			Mean \$, All Medicaid FFS \$d	Beneficiaries	Benefit Months
All	1.0	\$66	16.2	32.4	49.7	7.3	7.6	2.4	0.5	\$409	126,454	1,187,862
Age												
5 and younger	0.3	17	7.8	32.4	64.5	2.3	0.9	0.0	0.0	216	22,612	214,363
6-14	0.4	33	9.5	39.2	53.2	4.4	2.9	0.3	0.0	347	31,853	328,438
15-20	0.7	49	9.0	35.5	51.9	6.9	5.0	0.7	0.1	538	17,630	165,768
21-44	1.3	86	20.0	29.5	45.3	10.9	10.8	3.0	0.5	428	38,707	330,978
45-64	2.7	187	29.7	22.0	30.4	12.4	21.6	10.7	2.8	630	15,212	144,229
65-74	3.1	184	28.5	25.8	22.6	8.1	27.1	12.2	4.1	645	221	2,065
75-84	3.0	187	24.2	29.9	17.3	13.4	22.0	15.7	1.6	774	127	1,180
85 and older	3.5	191	11.3	37.0	8.7	9.8	18.5	20.7	5.4	1,696	92	841
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Basis of Eligibility	<sub>/</sub> e											
Aged	3.5	198	17.5	36.0	11.5	9.0	21.2	18.0	4.3	1,131	278	2,547
Disabled	3.3	271	16.0	13.7	30.0	12.3	24.4	14.3	5.3	1,693	9,117	101,325
Adults	1.3	81	24.4	29.5	43.8	11.2	12.0	3.2	0.3	332	49,443	420,132
Children	0.4	25	9.6	37.1	56.9	3.8	2.0	0.2	0.0	258	67,516	663,025
Unknown	1.4	85	9.6	26.0	40.0	15.0	16.0	2.0	1.0	886	100	833
Gender												
Female	1.1	71	18.2	28.1	51.3	8.4	8.5	3.0	0.7	389	68,603	651,930
Male	0.8	60	14.0	37.6	47.9	6.1	6.4	1.7	0.3	433	57,851	535,932
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Race												
White	1.3	84	17.5	26.8	49.8	9.0	10.1	3.5	0.8	483	72,333	700,429
African American	0.7	48	13.2	34.7	53.5	5.6	4.5	1.6	0.0	359	1,474	13,764
Other/unknown	0.6	40	13.3	40.1	49.6	5.1	4.1	0.9	0.1	301	52,647	473,669
Use of Nursing Fa	icilities <sup>f</sup>											
Entire year	9.9	674	11.2	4.6	0.0	4.6	20.7	31.0	39.1	6,038	87	844
Part year	8.7	553	9.6	0.8	9.8	6.1	22.7	28.8	31.8	5,730	132	1,368
None	1.0	65	16.3	32.5	49.8	7.3	7.5	2.4	0.5	399	126,235	1,185,650
Maintenance Assi	stance Status	;										
Cash	1.9	141	16.4	21.4	47.1	9.4	13.5	6.6	2.1	857	20,192	213,130
Medically needy	1.3	79	19.3	30.0	47.1	9.8	9.3	3.2	0.6	408	8,588	75,110
Poverty related	0.4	20	11.0	38.9	56.2	3.4	1.4	0.1	0.0	179	49,405	473,322
Other/unknown	1.2	78	17.8	30.9	44.7	10.0	11.0	3.0	0.4	440	48,269	426,300

a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5 AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC<sup>a, b, c</sup> NONDUAL BENEFICIARIES, VERMONT, 2005

		All Rx		Patented	ม Brand Drugs	d-Name	Off-Pater	nt Bran Drugs	d-Name	Gen	eric Dı	ugs
Beneficiary Characteristics	Number of Rx	Rx \$	\$ per Rx	Number of Rx		\$ per Rx	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx\$	\$ per Rx
All	1.0	\$66	\$67	0.4	\$50	\$134	0.0	\$3	\$91	0.6	\$13	\$23
Age			·		•	·						
5 and younger	0.3	17	48	0.1	13	118	0.0	0	33	0.2	4	15
6-14	0.4	33	77	0.2	28	124	0.0	1	87	0.2	4	22
15-20	0.7	49	72	0.3	39	132	0.0	2	71	0.4	8	23
21-44	1.3	86	64	0.5	62	137	0.0	4	91	0.8	19	23
45-64	2.7	187	69	1.0	137	139	0.1	10	111	1.6	41	25
65-74	3.1	184	60	1.2	139	118	0.1	8	80	1.8	37	21
75-84	3.0	187	62	1.2	148	125	0.1	4	47	1.8	35	20
85 and older	3.5	191	54	1.2	144	122	0.2	11	52	2.1	35	17
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	(
Basis of Eligibility	/d											
Aged	3.5	198	58	1.2	150	121	0.2	9	55	2.0	40	20
Disabled	3.3	271	81	1.3	207	156	0.1	14	115	1.9	49	26
Adults	1.3	81	61	0.4	58	130	0.0	4	86	0.8	19	23
Children	0.4	25	62	0.2	20	115	0.0	1	70	0.2	4	19
Unknown	1.4	85	60	0.5	70	135	0.0	2	57	0.9	13	15
Gender												
Female	1.1	71	62	0.4	52	127	0.0	3	80	0.7	16	22
Male	0.8	60	75	0.3	47	144	0.0	3	115	0.5	11	24
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	C
Race												
White	1.3	84	67	0.5	63	134	0.0	4	96	0.8	18	23
African American	0.7	48	70	0.3	37	142	0.0	3	129	0.4	8	21
Other/unknown	0.6	40	68	0.2	31	132	0.0	2	76	0.3	7	22
Use of Nursing Fa	cilitiese											
Entire year	9.9	674	68	3.4	494	145	0.4	41	113	6.1	138	23
Part year	8.7	553	64	2.7	357	133	0.3	25	95	5.7	171	30
None	1.0	65	67	0.4	49	134	0.0	3	91	0.6	13	23
Maintenance Assi	stance Sta	tus										
Cash	1.9	141	75	0.7	107	151	0.1	7	109	1.1	27	24
Medically needy	1.3	79	62	0.4	56	128	0.0	5	95	0.8	18	23
Poverty related	0.4	20	56	0.1	15	107	0.0	1	62	0.2	4	19
Other/unknown	1.2	78	65	0.4	58	131	0.0	4	86	0.7	16	23

a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Vermont, 0.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9ad778d7b6615 (October 26, 2007).

d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY<sup>a, b, c, d</sup>

NONDUAL BENEFICIARIES, VERMONT, 2005

		mber of R Month Am			\$ per	Benefit N Us		nong		\$ per	Rx					Users <sup>e</sup>	
Therapeutic Category	F Total	Patented Brand- Name	Brand-	Generic		atented Brand- Name		3eneric	P Total	atented Brand- Name	Brand-	Generic	Total Number of Rx	Total Rx \$	Number of	As a Percentage of All Benes	Number of Benefit Months
Anti-infective Agents	0.2	0.0	0.0	0.2	\$12	\$7	\$2	\$3	\$53	\$153	\$78	\$21	120,432	\$6,430,074	50,318	39.8	533,039
Biologicals	0.2	0.2	0.0	0.0	150	131	2	17	717	662	1,789	1,674	1,598	1,145,250	758	0.6	7,650
Antineoplastic Agents	0.5	0.2	0.0	0.4	128	109	2	16	235	678	162	43	2,873	675,527	505	0.4	5,297
Endocrine/Metabolic Drugs	0.5	0.2	0.0	0.3	28	18	3	7	55	101	61	26	110,329	6,035,897	20,787	16.4	215,292
Cardiovascular Agents	1.0	0.4	0.0	0.6	48	38	0	9	47	103	42	15	128,869	6,066,819	12,286	9.7	127,467
Respiratory Agents	0.4	0.2	0.0	0.2	27	23	1	3	65	103	68	15	113,000	7,309,466	25,690	20.3	273,445
Gastrointestinal Agents	0.5	0.3	0.0	0.2	49	46	0	3	101	153	80	18	58,991	5,956,223	11,447	9.1	120,684
Genitourinary Agents	0.2	0.1	0.0	0.1	15	11	2	2	60	93	62	21	12,040	720,540	4,591	3.6	49,105
CNS Drugs	0.9	0.4	0.0	0.5	76	61	1	13	84	149	152	27	228,238	19,159,179	24,587	19.4	252,545
Stimulants/Anti-obesity/Anorexia	0.8	0.6	0.0	0.1	75	69	1	5	96	109	95	37	48,925	4,685,390	5,723	4.5	62,297
Miscellaneous Psychological/ Neurological Agents	0.2	0.1	0.0	0.1	53	46	0	6	255	408	112	70	3,790	965,742	2 1,761	1.4	18,328
Analgesics and Anesthetics	0.6	0.1	0.0	0.5	28	14	3	11	48	143	231	23	171,352	8,177,643	28,750	22.7	295,113
Neuromuscular Agents	0.6	0.2	0.0	0.4	50	35	2	13	81	168	88	34	77,758	6,324,762	11,956	9.5	125,555
Nutritional Products	0.2	0.0	0.0	0.2	2	0	0	2	13	50	13	13	19,614	263,649	9,902	7.8	107,169
Hematological Agents	0.6	0.2	0.0	0.4	87	78	2	7	145	405	75	19	10,676	1,550,097	1,703	1.3	17,784
Topical Products	0.2	0.1	0.0	0.1	8	5	0	3	44	94	58	21	60,152	2,620,680	28,737	22.7	308,614
Miscellaneous Products	0.1	0.1	0.0	0.0	12	9	1	2	91	88	201	79	5,375	491,473	3,650	2.9	39,741
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	7	0	0	0	41	0	0	0	837	34,093	3 431	0.3	4,659
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	1,174,849	78,612,504	l n.a.	n.a.	n.a.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum

of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Vermont, 0.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005.

### TABLE ND.7 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP<sup>a, b, c</sup> NONDUAL BENEFICIARIES, VERMONT, 2005

			Users		An	nong Usei	S
Top 10 Drug Groups	Total Medicaid Rx	Number of Users	As a Percentage of All Beneficiaries	Number of Benefit Months		\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$9,503,263	7,277	5.8	79,176	0.6	\$192	\$120
ANTIDEPRESSANTS	8,492,957	26,063	20.6	271,607	0.5	64	31
ANTICONVULSANT	5,736,112	8,199	6.5	88,052	0.6	102	65
ANTIASTHMATIC	5,192,217	25,719	20.3	276,478	0.3	68	19
ANALGESICS - Narcotic	5,180,963	33,312	26.3	348,277	0.3	43	15
ULCER DRUGS	4,889,263	10,475	8.3	111,014	0.4	99	44
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	4,685,390	6,766	5.4	74,416	0.7	96	63
ANTIHYPERLIPIDEMIC	3,424,516	5,044	4.0	53,639	0.6	110	64
ANTIVIRAL	2,658,097	2,298	1.8	24,034	0.3	361	111
ANTIDIABETIC	2,464,980	4,544	3.6	47,618	0.7	76	52
Total	52,227,758	129,697		1,374,311	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$

<sup>=</sup> Medicaid reimbursement.

### TABLE ND.7A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, VERMONT, 2005

	All Top 10	Drug Groups			IPSYCHOTIC				AN <sup>-</sup>	TIDEPRESS	ANTS	
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users		Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Months Among	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month
All	605,756	\$52,227,758	7,277	5.8	79,176	0.6	\$120	26,063	20.6	271,607	0.5	\$31
Female												
All Females	365,422	29,584,167	3,967	5.8	43,352	0.6	105	18,220	26.6	191,443	0.5	32
Female, Disabled												
All Ages	123,730	11,688,174	1,608	33.6	18,587	0.8	157	3,674	76.7	42,379	0.6	40
5 and younger	666	60,502	6	4.8	72	0.8	124	3	2.4	36	0.7	31
6-14	4,709	561,715	98	21.4	1,153	0.7	149	94	20.6	1,100	0.6	27
15-20	5,909	565,763	125	29.1	1,466	0.9	122	226	52.6	2,637	0.6	35
21-44	42,711	4,100,284	718	42.8	8,320	0.7	136	1,498	89.2	17,404	0.6	40
45-64	69,052	6,353,734	658	31.9	7,556	0.9	189	1,840	89.3	21,066	0.7	41
65-74	665	44,666	3	9.4	20	2.8	428	13	40.6	136	0.7	42
75-84	16	1,495	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	2	15	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other Eligibles												
All Ages	241,692	17,895,993	2,359	3.7	24,765	0.4	66	14,546	22.8	149,064	0.4	30
5 and younger	4,848	301,122	7	0.1	76	0.4	53	8	0.1	68	0.2	11
6-14	20,744	1,666,643	263	1.8	3,021	0.5	97	632	4.2	7,071	0.4	22
15-20	22,663	1,623,495	452	5.3	4,954	0.5	85	1,719	20.0	18,080	0.4	23
21-44	127,152	8,790,800	1,290	5.7	13,226	0.3	50	8,977	39.6	91,609	0.4	29
45-64	64,262	5,346,382	333	5.1	3,357	0.5	70	3,165	48.7	31,776	0.6	38
65-74	1,064	89,022	3	3.2	36	0.8	213	22	23.4	214	0.7	33
75-84	410	32,530	4	6.1	38	0.5	59	13	19.7	145	0.6	18
85 and older	549	45,999	7	12.5	57	0.8	203	10	17.9	101	0.9	46
Male												
All Males	240,334	22,643,591	3,310	5.7	35,824	0.7	138	7,843	13.6	80,164	0.5	30
Male, Disabled												
All Ages	73,559	8,147,336	1,356	31.3	15,555	0.8	174	1,747	40.4	19,953	0.6	35
5 and younger	917	84,648	7	3.1	84	0.7	98	8	3.5	96	0.4	8
6-14	11,578	1,374,993	334	37.6	3,913	0.7	150	233	26.2	2,765	0.6	29
15-20	9,071	1,116,819	265	34.1	3,103	0.7	153	268	34.5	3,172	0.6	37
21-44	20,794	2,351,398	432	36.8	4,867	0.9	195	560	47.7	6,338	0.6	36
45-64	30,798	3,175,047	314	25.3	3,558	0.9	189	672	54.2	7,519	0.7	37
65-74	332	38,156	4	22.2	30	0.8		5	27.8		0.7	31
75-84	69	6,275	0	0.0	0	0.0	0	1	16.7		0.3	6
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

# TABLE ND.7A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, VERMONT, 2005

	All Top 10	Drug Groups		ANTI	PSYCHOTIC	S			AN'	TIDEPRESSA	ANTS	
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users		Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Months Among	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month
Male, Other Eligibles												
All Ages	166,775	14,496,255	1,954	3.7	20,269	0.6	111	6,096	11.4	60,211	0.4	28
5 and younger	8,568	585,361	31	0.3	360	0.5	85	24	0.2	282	0.3	6
6-14	40,964	3,620,163	619	4.0	7,073	0.6	115	852	5.5	9,549	0.5	26
15-20	19,609	1,777,103	381	4.9	4,122	0.7	132	867	11.1	9,348	0.5	28
21-44	55,321	4,622,828	679	5.2	6,329	0.5	98	2,869	21.8	26,475	0.4	27
45-64	40,425	3,722,864	227	4.2	2,208	0.5	89	1,448	26.8	14,196	0.5	32
65-74	728	58,727	4	5.2	36	0.7	208	9	11.7	93	0.8	46
75-84	640	56,304	6	11.5	65	0.7	67	11	21.2	120	0.5	22
85 and older	520	52,905	7	20.6	76	1.3	293	16	47.1	148	0.8	44
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

## ${\sf TABLE\;ND.7B}\\ {\sf MEDICAID\;PHARMACY\;BENEFIT\;USE\;AND\;REIMBURSEMENT\;FOR\;THIRD\;TO\;FIFTH\;TOP\;DRUG\;GROUPS\;SEPARATELY,}$

### BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, VERMONT, 2005

		ANTIO	CONVULSA	NT			ANT	TIASTHMATIC	С			ANALG	ESICS - Nar	cotic	
		Users as %	Number of Benefit N Months	Mean lumber of Rx per F	Mean		Users as %	Number of Benefit N Months	Mean Number of	Mean Rx \$ per		Users as %	Number of Benefit N Months	Mean lumber of	Mean Rx \$ per
Beneficiary Characteristics	Number of Users	of All Benes	Among			Number of Users	of All Benes	Among Users	Benefit Month		Number of Users	of All Benes	Among	Benefit Month	Benefit
All	8,199	6.5	88,052	0.6	\$65	25,719	20.3	276,478	0.3	\$19	33,312	26.3	348,277	0.3	\$15
Female	,		,			,		•		·	,		,		•
All Females	5,245	7.6	57,110	0.6	62	15,026	21.9	162,211	0.3	19	21,532	31.4	230,408	0.3	13
Female, Disabled															
All Ages	1,890	39.5	21,770	0.8	85	2,514	52.5	29,101	0.4	31	3,501	73.1	40,586	0.5	26
5 and younger	25	20.0	298	0.6	81	65	52.0	751	0.2	17	12	9.6	141	0.1	1
6-14	119	26.0	1,379	0.9	148	140	30.6	1,629	0.3	16	42	9.2	497	0.1	1
15-20	101	23.5	1,193	1.0	103	124	28.8	1,456	0.2	18	108	25.1	1,265	0.1	2
21-44	829	49.4	9,621	0.8	86	819	48.8	9,573	0.3	23	1,537	91.5	17,899	0.4	21
45-64	811	39.3	9,219	0.9	74	1,353	65.6	15,566	0.4	39	1,789	86.8	20,656	0.6	34
65-74	5	15.6	60	1.4	26	13	40.6	126	0.6	62	13	40.6	128	0.6	11
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other Eligibles															
All Ages	3,355	5.3	35,340	0.5	48	12,512	19.6	133,110	0.3	17	18,031	28.3	189,822	0.3	10
5 and younger	44	0.4	501	0.3	46	1,737	16.1	18,960	0.2	12	266	2.5	2,910	0.1	1
6-14	140	0.9	1,604	0.6	86	2,593	17.3	28,766	0.2	14	750	5.0	8,456	0.1	1
15-20	258	3.0	2,684	0.4	48	1,635	19.0	17,540	0.2	12	2,321	27.0	24,390	0.2	3
21-44	2,139	9.4	22,453	0.5	43	4,721	20.8	48,830	0.3	16	11,853	52.3	123,987	0.3	12
45-64	758	11.7	7,927	0.6	55	1,771	27.2	18,470	0.4	32	2,795	43.0	29,585	0.4	13
65-74	5	5.3	60	0.6	9	34	36.2	354	0.6	57	23	24.5	273	0.4	29
75-84	6	9.1	53	0.3	10	15	22.7	140	0.3	32	12	18.2	120	0.2	9
85 and older	5	8.9	58	0.8	45	6	10.7	50	0.4	50	11	19.6	101	0.8	38
Male															
All Males	2,954	5.1	30,942	0.7	71	10,693	18.5	114,267	0.3	18	11,780	20.4	117,869	0.4	19
Male, Disabled															
All Ages	1,090	25.2	12,501	0.8	92	1,243	28.7	14,360	0.3	27	1,665	38.5	18,906	0.5	33
5 and younger	33	14.6	383	0.5	73	105	46.5	1,223	0.3	25	18	8.0	211	0.1	1
6-14	169	19.0	1,971	0.7	93	238	26.8	2,801	0.3	16	66	7.4	786	0.2	2
15-20	141	18.2	1,646	0.9	135	156	20.1	1,846	0.3	12	143	18.4	1,681	0.2	5
21-44	376	32.0	4,277	0.9	102	238	20.3	2,706	0.3	20	592	50.4	6,668	0.5	27
45-64	368	29.7	4,188	0.8	66	496	40.0	5,664	0.4	39	837	67.6	9,460	0.6	45
65-74	3	16.7	36	0.8	34	8	44.4	96	0.9	110	8	44.4	88	0.5	64
75-84	0	0.0	0	0.0	0	2	33.3	24	0.3	48	1	16.7	12	0.1	1
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

### TABLE ND.7B MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,

### BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, VERMONT, 2005

		ANTIC	CONVULSAN	NT			ANT	TASTHMATIC	)			ANALO	SESICS - Nar	cotic	
		ı	Number of	Mean				Number of	Mean				Number of	Mean	
		Users	Benefit N	lumber of	Mean		Users	Benefit N	lumber of	Mean		Users	Benefit N	lumber of	Mean
		as %	Months	Rx per	Rx \$ per		as %	Months	Rx per l	Rx \$ per		as %	Months	Rx per	Rx \$ per
Description Of the state of the	Number of	of All	Among	Benefit			of All	Among			Number of	of All	Among		Benefit
Beneficiary Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month
Male, Other Eligibles															
All Ages	1,864	3.5	18,441	0.6	57	9,450	17.7	99,907	0.3	17	10,115	18.9	98,963	0.4	16
5 and younger	52	0.5	569	0.6	81	2,696	23.5	29,463	0.2	13	426	3.7	4,802	0.1	1
6-14	222	1.4	2,472	0.7	85	3,396	21.9	37,581	0.2	14	843	5.4	9,508	0.1	1
15-20	184	2.4	1,957	0.6	78	1,036	13.2	10,739	0.2	13	1,314	16.8	13,514	0.2	3
21-44	900	6.8	8,380	0.5	44	1,388	10.5	12,785	0.3	20	5,402	41.0	49,751	0.5	23
45-64	492	9.1	4,910	0.6	52	894	16.5	8,899	0.4	38	2,095	38.7	21,010	0.4	18
65-74	7	9.1	84	0.9	37	18	23.4	216	0.4	32	14	18.2	145	0.3	13
75-84	4	7.7	44	1.0	212	8	15.4	92	0.9	62	12	23.1	127	0.3	4
85 and older	3	8.8	25	0.8	28	14	41.2	132	0.5	36	9	26.5	106	0.4	6
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

## ${\it TABLE~ND.7C}\\ {\it MEDICAID~PHARMACY~BENEFIT~USE~AND~REIMBURSEMENT~FOR~SIXTH~TO~EIGHTH~TOP~DRUG~GROUPS~SEPARATELY,}$

### BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, VERMONT, 2005

		ULO	CER DRUGS			STIMULA	NTS/ANT	I-OBESITY/	ANOREXIA	ANTS		ANTIHY	/PERLIPIDE	EMIC	
Beneficiary Characteristics	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users	Mean lumber of Rx per l Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users		Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit I Months Among Users		Mean Rx \$ per Benefit Month
All	10,475	8.3	111,014	0.4	\$44	6,766	5.4	74,416	0.7	\$63	5,044	4.0	53,639	0.6	\$64
Female															
All Females	6,797	9.9	73,286	0.4	44	2,235	3.3	24,528	0.6	60	2,752	4.0	29,779	0.6	65
Female, Disable	t														
All Ages	1,804	37.7	20,916	0.6	58	382	8.0	4,455	0.7	73	972	20.3	11,268	0.7	70
5 and younger	21	16.8	246	0.7	45	4	3.2	48	0.5	41	0	0.0	0	0.0	0
6-14	29	6.3	337	0.5	37	127	27.8	1,484	0.8	76	1	0.2	12	0.6	20
15-20	62	14.4	718	0.5	31	73	17.0	857	0.7	77	0	0.0	0	0.0	0
21-44	605	36.0	7,087	0.5	50	111	6.6	1,311	0.6	55	167	9.9	1,970	0.6	65
45-64	1,073	52.1	12,381	0.7	65	67	3.3	755	0.7	94	790	38.3	9,143	0.7	71
65-74	13	40.6	135	0.5	47	0	0.0	0	0.0	0	12	37.5	119	0.5	52
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	66.7	24	0.4	33
85 and older	1	100.0	12	0.2	1	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other El	igibles														
All Ages	4,993	7.8	52,370	0.4	39	1,853	2.9	20,073	0.6	57	1,780	2.8	18,511	0.5	62
5 and younger	222	2.1	1,998	0.3	19	26	0.2	303	0.2	19	21	0.2	226	0.1	2
6-14	301	2.0	3,429	0.2	17	883	5.9	9,835	0.6	57	3	0.0	35	0.4	22
15-20	475	5.5	5,082	0.2	15	352	4.1	3,799	0.6	55	8	0.1	81	0.4	37
21-44	2,511	11.1	26,411	0.3	35	459	2.0	4,789	0.5	59	463	2.0	4,885	0.4	52
45-64	1,427	22.0	14,854	0.5	61	132	2.0	1,343	0.6	65	1,240	19.1	12,798	0.6	67
65-74	26	27.7	274	0.6	49	1	1.1	4	0.5	65	28	29.8	300	0.7	71
75-84	15	22.7	153	0.6	59	0	0.0	0	0.0	0	11	16.7	117	0.6	77
85 and older	16	28.6	169	0.6	55	0	0.0	0	0.0	0	6	10.7	69	0.8	129
Male															
All Males	3,678	6.4	37,728	0.4	43	4,531	7.8	49,888	0.7	65	2,292	4.0	23,860	0.6	62
Male, Disabled															
All Ages	920	21.3	10,495	0.6	53	813	18.8	9,518	0.8	77	591	13.7	6,841	0.7	65
5 and younger	27	11.9	316	0.5	37	22	9.7	256	0.3	19	3	1.3	36	0.3	13
6-14	61	6.9	722	0.4	27	469	52.8	5,487	0.8	81	2	0.2	24	0.3	21
15-20	71	9.1	840	0.4	29	234	30.2	2,760	0.8	78	4	0.5	48	0.7	56
21-44	274	23.3	3,108	0.6	52	58	4.9	670	0.6	57	128	10.9	1,472	0.7	53
45-64	481	38.8	5,445	0.7	62	30	2.4	345	0.7	94	442	35.7	5,125	0.7	69
65-74	4	22.2	40	0.6	58	0	0.0	0	0.0	0	10	55.6	112	0.6	58
75-84	2	33.3	24	0.9	58	0	0.0	0	0.0	0	2	33.3	24	1.0	135
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

### TABLE ND.7C MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,

### BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, VERMONT, 2005

		ULO	CER DRUGS			STIMULA	NTS/ANT	I-OBESITY/	ANOREXIA	ANTS		ANTIH	IYPERLIPIDE	EMIC	
			Number of	Mean				Number of	Mean				Number of	Mean	
		Users	Benefit N	umber of	Mean		Users	Benefit N	lumber of	Mean		Users	Benefit I	Number of	Mean
		as %	Months	Rx per l	Rx \$ per		as %	Months	Rx per l	Rx \$ per		as %	Months	Rx per	Rx \$ per
Beneficiary	Number of	of All	Among	Benefit	Benefit	Number of	of All	Among	Benefit	Benefit	Number of	of All	Among	Benefit	Benefit
Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month
Male, Other Elig	ibles														
All Ages	2,758	5.2	27,233	0.4	40	3,718	6.9	40,370	0.7	62	1,701	3.2	17,019	0.5	61
5 and younger	324	2.8	3,011	0.3	21	91	8.0	1,046	0.4	34	24	0.2	258	0.1	3
6-14	236	1.5	2,644	0.3	20	2,481	16.0	27,637	0.7	61	2	0.0	23	0.3	13
15-20	243	3.1	2,566	0.3	24	771	9.8	8,193	0.6	65	11	0.1	115	0.3	30
21-44	1,090	8.3	10,264	0.4	42	299	2.3	2,733	0.6	61	458	3.5	4,494	0.5	56
45-64	816	15.1	8,228	0.5	54	75	1.4	756	0.5	72	1,161	21.5	11,658	0.6	65
65-74	19	24.7	192	0.5	48	1	1.3	5	0.4	23	21	27.3	208	0.6	69
75-84	17	32.7	182	0.7	58	0	0.0	0	0.0	0	19	36.5	213	0.7	76
85 and older	13	38.2	146	0.7	77	0	0.0	0	0.0	0	5	14.7	50	0.6	85
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

## TABLE ND.7D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS

# SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, VERMONT, 2005

			ANTIVIRAL				1A	NTIDIABETIC				
Beneficiary Characteristics	Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users	Mean lumber of Rx per F Benefit Month		Number of Users	Users as % of All Benes	Number of Benefit N Months Among Users	Mean Iumber of Rx per F Benefit Month		Number of Beneficiaries	Number of Benefit Months
All	2,298	1.8	24,034	0.3	\$111	4,544	3.6	47,618	0.7	\$52	126,454	1,187,862
Female												
All Females	1,640	2.4	17,287	0.3	66	2,747	4.0	29,254	0.7	50	68,603	651,930
Female, Disabled	t											
All Ages	256	5.3	2,950	0.4	105	1,013	21.2	11,555	0.7	53	4,788	53,578
5 and younger	2	1.6	24	0.2	17	1	0.8	12	0.4	7	125	1,406
6-14	5	1.1	60	0.1	3	8	1.8	96	0.7	44	457	5,245
15-20	16	3.7	192	0.5	204	20	4.7	234	0.6	71	430	4,840
21-44	125	7.4	1,448	0.4	120	244	14.5	2,815	0.6	47	1,679	18,882
45-64	107	5.2	1,222	0.3	78	724	35.1	8,215	0.8	55	2,061	22,834
65-74	1	3.1	4	0.3	13	15	46.9	171	0.9	42	32	323
75-84	0	0.0	0	0.0	0	1	33.3	12	0.6	60	3	36
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	12
Female, Other El	igibles											
All Ages	1,384	2.2	14,337	0.3	58	1,734	2.7	17,699	0.6	48	63,815	598,352
5 and younger	39	0.4	416	0.1	6	5	0.0	59	0.5	51	10,798	101,809
6-14	95	0.6	1,064	0.2	14	52	0.3	572	0.7	79	15,026	154,146
15-20	167	1.9	1,701	0.2	26	91	1.1	973	0.6	58	8,595	79,819
21-44	854	3.8	8,655	0.3	61	706	3.1	7,057	0.6	45	22,680	199,952
45-64	224	3.4	2,447	0.3	100	845	13.0	8,631	0.7	48	6,500	60,655
65-74	0	0.0	0	0.0	0	16	17.0	182	0.8	59	94	872
75-84	0	0.0	0	0.0	0	9	13.6	108	0.6	33	66	594
85 and older	5	8.9	54	0.1	5	10	17.9	117	0.9	21	56	505
Male												
All Males	658	1.1	6,747	0.4	224	1,797	3.1	18,364	0.7	54	57,851	535,932
Male, Disabled												
All Ages	132	3.0	1,495	0.6	365	505	11.7	5,727	0.7	54	4,329	47,747
5 and younger	4	1.8	39	0.1	5	0	0.0	0	0.0	0	226	2,463
6-14	6	0.7	71	0.1	5	17	1.9	204	0.6	62	888	10,124
15-20	10	1.3	120	0.5	164	15	1.9	176	0.7	52	776	8,777
21-44	55	4.7	618	0.5	267	106	9.0	1,188	0.7	54	1,175	12,754
45-64	57	4.6	647	0.7	558	363	29.3	4,111	0.7	54	1,239	13,346
65-74	0	0.0	0	0.0	0	2	11.1	24	0.8	68	18	199
75-84	0	0.0	0	0.0	0	2	33.3	24	0.5	17	6	72
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	12

### TABLE ND.7D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS

### SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> NONDUAL BENEFICIARIES, VERMONT, 2005

ANTIVIRAL ANTIDIABETIC Number of Mean Number of Mean Users Benefit Number of Mean Users Benefit Number of Mean as % Months Rx per Rx \$ per as % Months Rx per Rx \$ per Beneficiary Number of of All Among Benefit Benefit Number of of All Among Benefit Benefit Number of Number of Characteristics Users Benes Month Users Month Month Beneficiaries Benefit Months Users Month Benes Users Male, Other Eligibles 53,522 All Ages 526 1.0 5,252 0.3 184 1,292 2.4 12,637 0.7 55 488,185 5 and younger 51 0.4 580 0.1 5 25 0.2 259 0.6 85 11,463 108,685 69 63 6-14 0.4 796 0.2 15 60 0.4 670 0.6 15,482 158,923 15-20 59 0.8 610 0.2 11 49 0.6 473 0.7 84 7,829 72,332 21-44 226 1.7 2.012 0.4 219 395 3.0 3.700 0.7 60 13.173 99.390 48 5,412 47,394 45-64 117 2.2 1,206 0.5 420 728 13.5 7,141 0.7 77 671 65-74 0 0.0 0 0.0 0 22 28.6 241 0.8 48 52 478 75-84 2 3.8 24 0.1 2 10 19.2 119 0.9 59 2 24 6 68 34 312 5.9 0.3 8.8 34 85 and older 3 1.0 Unknown 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0 0

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy; \$ = Medicaid reimbursement.

### TABLE ND.8 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC<sup>a, b</sup>

### NONDUAL BENEFICIARIES, VERMONT, 2005

Danafialani		Number of Dynas Deposit	Number of All Veer Number	Benefit Months Among All-
Beneficiary Characteristics	Rx \$ per Benefit Month	Month	Number of All-Year Nursing Facility Residents	Year Nursing Facility Residents
All	\$674	9.9	<b>'</b>	844
Age				
0-64	861	12.1	51	535
65-74	380	5.4	6	43
75-84	250	5.7	8	67
85 and older	379	6.4	22	199
Unknown	0	0.0	0	0
Gender				
Female	643	9.6	61	618
Male	761	10.7	26	226
Unknown	0	0.0	0	0
Race				
White	722	10	67	681
African American	0	0	0	0
Other/unknown	475	9.6	20	163
Basis of Eligibility				
Aged	338	6.0	33	302
Disabled	858	12.1	53	541
Adults	0	0.0	0	0
Children	0	0.0	0	0
Unknown	3,002	12.0	1	1

c. inedicate basis or eligibility is classified as, aged, disabled, adultis, and children't ne disabled group includes behaliciant or all yage who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicard Services; MAX = Medicard Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicard reimbursement.

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.
a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2005 Medicaid enrollment. A total of 132 beneficiaries who were

in nursing facilities for part of their enrollment and their 1,368 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

### TABLE ND.9 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

### BY BRAND STATUS AND THERAPEUTIC CATEGORY<sup>a, b, c, d, e</sup> NONDUAL BENEFICIARIES, VERMONT, 2005

Therapeutic	Р	atented Brand-	Brand-				Brand-			atented Brand-	Brand-		Total Number		Number of	Facility	Benefit
Category	Total	Name	Name G	Seneric	Total	Name	Name G	eneric	Total	Name	Name G	eneric	of Rx	Total Rx \$	Users	Residents	Months
Anti-infective Agents	0.7	0.2	0.0	0.5	\$30	\$15	\$5	\$9	\$40	\$85	\$118	\$18	556	\$22,474	70	80.5	750
Biologicals	0.1	0.0	0.0	0.1	4	0	0	4	29	0	0	29	5	146	5	5.7	38
Antineoplastic Agents	1.0	0.4	0.0	0.6	137	118	0	19	133	268	0	33	35	4,672	4	4.6	34
Endocrine/Metabolic Drugs	1.6	0.6	0.2	8.0	113	46	51	16	68	74	218	20	758	51,849	45	51.7	460
Cardiovascular Agents	2.0	0.3	0.0	1.6	49	27	0	22	25	79	17	13	1,057	26,045	55	63.2	530
Respiratory Agents	0.8	0.5	0.0	0.3	64	60	0	4	76	113	7	13	290	21,936	34	39.1	343
Gastrointestinal Agents	1.3	0.7	0.1	0.5	110	95	3	12	82	130	38	23	610	49,973	47	54.0	455
Genitourinary Agents	1.0	0.5	0.0	0.4	56	41	1	14	58	77	39	34	235	13,616	25	28.7	243
CNS Drugs	2.4	1.3	0.0	1.1	290	267	1	22	123	208	60	21	1,773	218,101	75	86.2	752
Stimulants/Anti-obesity/Anorexia	0.3	0.3	0.0	0.0	42	42	0	0	168	168	0	0	1	168	1	1.1	4
Miscellaneous Psychological/ Neurological Agents	0.9	0.9	0.0	0.0	195	194	0	1	217	218	0	85	115	24,931	13	14.9	128
Analgesics and Anesthetics	1.5	0.3	0.0	1.1	62	23	7	32	42	97	76	28	717	30,422	51	58.6	489
Neuromuscular Agents	1.8	0.2	0.0	1.3	121	65	1	55	69	162	23	42	970	66,505	51	58.6	548
Nutritional Products	1.1	0.4								3			263	,		26.4	230
			0.0	1.1	23	0	0	23	21	-	0	21		5,393	23		
Hematological Agents	2.0	0.2	0.1	1.8	45	26	2	17	23	153	27	10	609	13,708	31	35.6	302
Topical Products	0.6	0.3	0.0	0.3	33	22	1	11	56	82	51	34	316	17,768	48	55.2	532
Miscellaneous Products	0.1	0.0	0.0	0.1	2	1	0	0	14	28	0	4	5	68	4	4.6	43
Unknown Therapeutic Category	0.3	0.0	0.0	0.0	11	0	0	0	38	0	0	0	35	1,336	11	12.6	121
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	8,350	569,111	n.a.	n.a.	n.a.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 132 beneficiaries who were in nursing facilities for part of their enrollment and their 1,368 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

In Vermont, 0.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

### TABLE ND.10 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

### BY TOP-10 DRUG GROUPa, b, c, d NONDUAL BENEFICIARIES, VERMONT, 2005

			Users				Among Users
Top 10 Drug Groups in Nursing Facilities	Total Medicaid Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Monthsp	Number of Rx er Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$168,232	62	71.3	682	1.0	\$242	\$247
ANTICONVULSANT	52,159	50	57.5	546	1.2	82	96
ANTIDEPRESSANTS	41,591	76	87.4	788	1.0	55	53
ULCER DRUGS	39,189	49	56.3	495	0.9	91	79
MISC. ENDOCRINE	26,068	11	12.6	106	0.8	310	246
MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL ANTIDIABETIC	25,374 20,506	16 34	18.4 39.1	169 377	0.8 1.0	195 53	150 54
ANTIASTHMATIC	18,273	40	46.0	377	0.5	91	48
ANALGESICS - Narcotic	18,480	59	67.8	605	0.8	36	31
DERMATOLOGICAL	14,540	93	106.9	1,027	0.3	54	14
Total	424,412	490		5,172	n.a.	n.a.	n.a.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$= Medicaid reimbursement.

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.
a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 132 beneficiaries who were in nursing facilities for part of their enrollment and their 1,368 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

### TABLE ND.10A

### MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGEA, b, c, d NONDUAL BENEFICIARIES, VERMONT, 2005

	All Top 10 Di	ug Groups		ANTIPS	CHOTICS				ANTICO	NVULSANT		
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among			Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among I Users	Mean Number of Rx	
All	4,103	\$424,412	62	71.3	682	1.0	\$247	50	57.5	546	1.2	\$96
Female												
All Females	3,010	302,585	49	80.3	538	1.0	245	37	60.7	403	1.1	82
Female, Disabled												
All Ages	2,448	259,688	40	102.6	460	1.0	246	30	76.9	344	1.2	93
64 or younger	2,418	254,655	38	105.6	452	1.0	243	30	83.3	344	1.2	93
65-74	30	5,033	2	66.7	8	0.9	391	0	0.0	0	0.0	0
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other Eligibles												
All Ages	562	42,897	9	40.9	78	1.0	243	7	31.8	59	0.9	22
64 or younger	5	974	0	0.0	0	0.0	0	1	100.0	1	2.0	92
65-74	67	5,850	1	100.0	12	1.5	435	1	100.0	12	0.9	21
75-84	94	5,140	2	33.3	15	1.1	145	2	33.3	12	0.8	8
85 and older	396	30,933	6	42.9	51	0.8	226	3	21.4	34	1.0	25
Male												
All Males	1,093	121,827	13	50.0	144	1.1	252	13	50.0	143	1.3	133
Male, Disabled												
All Ages	813	91,396	6	42.9	72	1.0	240	8	57.1	94	1.5	184
64 or younger	813	91,396	6	42.9	72	1.0	240	8	57.1	94	1.5	184
65-74	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male, Other Eligibles												
All Ages	280	30,431	7	58.3	72	1.1	264	5	41.7	49	0.9	34
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	55	2,249	0	0.0	0	0.0	0	3	150.0	36	1.0	44
75-84	53	2,390	2	100.0	18	0.3	10	1	50.0	9	0.2	5
85 and older	172	25,792	5	62.5	54	1.4	348	1	12.5	4	1.3	6
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 132 beneficiaries who were

a. Table No. To includes the beneficiales represented by Cell LO in Table 1, those with resided in This gradies throughout their wedical enfollment in 2005. A local of 132 beneficialists who were in nursing facilities for part of their enrollment and their 1,368 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state. d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters

Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007). Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

### TABLE ND.10B

### MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY

AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c, d</sup>
NONDUAL BENEFICIARIES, VERMONT, 2005

		ANTIDEP	RESSANTS				ULCEF	RDRUGS				MISC. EN	NDOCRINE		
Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among	Mean Number of Rx		Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among	Mean Number of Rx		Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months	Mean Number of Rx	
All	76	87.4	788	1.0	\$53	49	56.3	495	0.9	\$79	11	12.6	106	0.8	
Female															
All Females	47	77.0	521	1.0	59	37	60.7	382	0.8	68	8	13.1	79	0.8	84
Female, Disable	ed														
All Ages	38	97.4	429	1.1	61	26	66.7	269	0.9	84	5	12.8	52	0.9	103
64 or younger	36	100.0	424	1.1	61	24	66.7	264	0.9	83	4	11.1	48	0.9	10
65-74	2	66.7	5	0.4	62	2	66.7	5	1.2	141	1	33.3	4	1.0	70
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
Female, Other E	Eligibles														
All Ages	9	40.9	92	1.0	48	11	50.0	113	0.6	29	3	13.6	27	0.6	46
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(
65-74	0	0.0	0	0.0	0	1	100.0	12	1.0	13	0	0.0	0	0.0	(
75-84	2	33.3	15	0.9	49	2	33.3	24	0.2	6	0	0.0	0	0.0	(
85 and older	7	50.0	77	1.0	48	8	57.1	77	0.7	38	3	21.4	27	0.6	46
Male															
All Males	29	111.5	267	0.8	41	12	46.2	113	1.1	119	3	11.5	27	0.7	72
Male, Disabled															
All Ages	19	135.7	182	0.9	47	11	78.6	107	1.1	125	1	7.1	12	1.0	1,582
64 or younger	19	135.7	182	0.9	47	11	78.6	107	1.1	125	1	7.1	12	1.0	1,582
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(
Male, Other Elig	jibles														
All Ages	10	83.3	85	0.7	30	1	8.3	6	1.0	9	2	16.7	15	0.5	33
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(
65-74	1	50.0	12	0.8	42	0	0.0	0	0.0	0	0	0.0	0	0.0	(
75-84	4	200.0	36	0.7	11	0	0.0	0	0.0	0	1	50.0	9	0.8	46
85 and older	5	62.5		0.7	45	1	12.5	6	1.0		1	12.5	6		
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 132 beneficiaries who were in nursing facilities for part of their enrollment and their 1,368 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. wedicald relinibisherient and action of the control of the cont

### TABLE ND.10C

### MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGEA, b, c, d

NONDUAL BENEFICIARIES, VERMONT, 2005

	MISC		HERAPEUT OLOGICAL	IC AND			ANTII	DIABETIC				ANTIAS	STHMATIC		
		Users as	Number of Benefit				Users as	Number of Benefit				Users as	Number of Benefit		
Beneficiary Characteristics	Number of Users	Nursing Facility	Months Among	Mean Number of Rx		Number of Users	Nursing Facility	Months	Mean Number of Rx		Number of Users	Nursing Facility Residents	Months	Mean Number of Rx	
All	16	18.4	169	0.8	\$150	34	39.1	377	1.0	\$54	40	46.0	377	0.5	
Female															
All Females	11	18.0	115	0.8	176	22	36.1	263	1.1	57	25	41.0	248	0.5	48
Female, Disable	ed														
All Ages	7	17.9	76	0.6	196	15	38.5	180	1.1	70	19	48.7	198	0.5	58
64 or younger	6	16.7	72	0.7	205	15	41.7	180	1.1	70	16	44.4	192	0.5	58
65-74	1	33.3	4	0.3	39	0	0.0	0	0.0	0	3	100.0	6	0.7	60
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
Female, Other E	Eligibles														
All Ages	4	18.2	39	1.1	137	7	31.8	83	1.0	29	6	27.3	50	0.2	: 7
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	, C
75-84	1	16.7	3	1.3	16	1	16.7	12	1.8	85	1	16.7	12	0.2	. 1
85 and older	3	21.4	36	1.0	147	6	42.9	71	0.9	19	5	35.7	38	0.2	: 8
Male															
All Males	5	19.2	54	0.8	95	12	46.2	114	0.9	49	15	57.7	129	0.7	49
Male, Disabled															
All Ages	1	7.1	12	0.2	13	11	78.6	102	1.0	53	9	64.3	93	0.7	56
64 or younger	1	7.1	12	0.2	13	11	78.6	102	1.0	53	9	64.3	93	0.7	56
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	, C
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	, C
Male, Other Elig	jibles														
All Ages	4	33.3	42	0.9	119	1	8.3	12	0.8	12	6	50.0	36	0.6	33
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	, C
65-74	0	0.0	0	0.0	0	1	50.0	12	0.8	12	0	0.0	0	0.0	, C
75-84	2	100.0	18	0.7	74	0	0.0	0	0.0	0	0	0.0	0	0.0	, C
85 and older	2	25.0	24	1.1	152	0	0.0	0	0.0	0	6	75.0	36	0.6	33
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	, C

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 132 beneficiaries who were in nursing facilities for part of their enrollment and their 1,368 benefit months were excluded from the analysis.

In hulasing racinities for part of their entolimite and trief in Jobs benefit and trief in Jobs benefit informs were excluded inform the analysis.

In Auser is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

C. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

### TABLE ND.10D

### MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c, d</sup>

NONDUAL BENEFICIARIES, VERMONT, 2005

ANALGESICS - Narcotic

DERMATOLOGICAL

Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months	Mean Number of Rx	Mean Rx \$	All-Year Nursing Facility Residents	Benefit Months Among All- Year Nursing Facility Residents
All	59	67.8	605	0.8	\$31	93	106.9	1,027	0.3	\$14	87	844
Female												
All Females	48	78.7	495	0.9	35	64	104.9	710	0.3	15	61	618
Female, Disable	ed											
All Ages	35	89.7	372	0.9	31	57	146.2	636	0.3	16	39	411
64 or younger	32	88.9	363	0.9	32	57	158.3	636	0.3	16	36	404
65-74	3	100.0	9	0.7	7	0	0.0	0	0.0	0	3	7
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Female, Other E	ligibles											
All Ages	13	59.1	123	0.9	45	7	31.8	74	0.2	4	22	207
64 or younger	1	100.0	1	3.0	882	0	0.0	0	0.0	0	1	1
65-74	1	100.0	12	2.0	15	1	100.0	12	0.2	4	1	12
75-84	5	83.3	60	0.3	13	1	16.7	12	0.4	11	6	57
85 and older	6	42.9	50	1.3	73	5	35.7	50	0.2	2	14	137
Male												
All Males	11	42.3	110	0.7	13	29	111.5	317	0.3	13	26	226
Male, Disabled												
All Ages	10	71.4	98	0.7	14	25	178.6	269	0.3	14	14	130
64 or younger	10	71.4	98	0.7	14	25	178.6	269	0.3	14	14	130
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Male, Other Elig	jibles											
All Ages	1	8.3	12	0.3	2	4	33.3	48	0.2	7	12	96
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	24
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	10
85 and older	1	12.5	12	0.3	2	4	50.0	48	0.2	7	8	62
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 132 beneficiaries who were in nursing facilities for part of their enrollment and their 1,368 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

### TABLE ND.11 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTICa,b VERMONT, 2005

Beneficiary Characteristics	Number of Beneficiaries with at Least One Part D Excluded Rx	Percentage of Beneficiaries with at Least One Part D Excluded Rx	Number of Part D Excluded Rx per Beneficiary	Total Number Part D Excluded Rx	\$ per	Total Part D Excluded Rx \$		Part D Excluded Rx \$ as a ercentage of All Nondual Rx \$	Total Number of Beneficiaries
All	26,029	20.6	0.9	109,093	\$15	\$1,925,964	\$18	2.4	126,454
Age									
5 and younger	3,289	14.5	0.3	6,220	5	114,930	18	3.2	22,612
6-14	4,335	13.6	0.3	9,940	10	323,024	32	3.0	31,853
15-20	2,805	15.9	0.4	7,272	7	119,530	16	1.5	17,630
21-44	9,938	25.7	1.1	44,014	19	732,842	17	2.6	38,707
45-64	5,498	36.1	2.7	40,411	41	619,357	15	2.3	15,212
65-74	78	35.3	2.4	540	34	7,582	14	2.0	221
75-84	50	39.4	2.7	343	37	4,748	14	2.1	127
85 and older	36	39.1	3.8	353	43	3,951	11	2.5	92
Unknown	0	0.0	0.0	0	0	0	0	0.0	0
Basis of Eligibility <sup>c</sup>									
Aged	102	36.7	3.2	899	41	11,336	13	2.2	278
Disabled	4,225	46.3	4.4	39,859	74	674,774	17	2.5	9,117
Adults	12,329	24.9	1.0	49,281	16	797,564	16	2.3	49,443
Children	9,344	13.8	0.3	18,926	7	439,649	23	2.7	67,516
Unknown	29	29.0	1.3	128	26	2,641	21	3.7	100
Gender									
Female	16,839	24.5	1.1	74,849	18	1,268,754	17	2.7	68,603
Male	9,190	15.9	0.6	34,244	11	657,210	19	2.0	57,851
Unknown	0	0.0	0.0	0	0	0	0	0.0	0
Race									
White	18,560	25.7	1.2	87,035	21	1,501,958	17	2.5	72,333
African American	309	21.0	0.6	880	9	12,725	14	1.9	1,474
Other/unknown	7,160	13.6	0.4	21,178	8	411,281	19	2.2	52,647
Use of Nursing Fac	ilities <sup>d</sup>								
Entire year	61	70.1	11.3	983	164	14,234	14	2.5	87
Part year	117	88.6	12.7	1,677	432	57,070	34	7.5	132
None	25,851	20.5	0.8	106,433	15	1,854,660	17	2.4	126,235
Maintenance Assis	tance Status								
Cash	6,845	33.9	2.2	44,913	37	754,327	17	2.5	20,192
Medically needy	2,123	24.7	1.0	8,937	16	133,964	15	2.3	8,588
Poverty related	6,202	12.6	0.2	12,002	6	287,849	24	3.1	49,405
Other/unknown e from the MAX 2005 file for	10,859	22.5	0.9	43,241	16	749,824	17	2.2	48,269

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

# TABLE ND.12 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup> VERMONT, 2005

Beneficiary ! Characteristics	Number Rx per	Rx \$ per Benefit Month	\$ per Rx	Barbiturate \$ per Benefit Month	Benzodiazepine \$ per Benefit Month	Number of Benefit Months
All	<b>0.1</b>	\$2	\$ per RX	\$0	per Benefit Month	1,187,862
Age	0.1	ΨZ	Ψισ	Ψ	Ψ1	1,107,002
5 and younger	0.0	1	18	0	0	214,363
6-14	0.0	1	32	0	0	328,438
15-20	0.0	1	16	0	0	165,768
21-44	0.0	2	17	0	1	330,978
45-64	0.3	4	15	0	2	144,229
65-74	0.3	4	14	0	1	2,065
75-84	0.3	4	14	0	1	1,180
85 and older	0.4	5	11	0	1	841
Unknown	0.0	0	0	0	0	0
Basis of Eligibility <sup>c</sup>		_		_	•	_
Aged	0.4	4	13	0	1	2,547
Disabled	0.4	7	17	0	3	101,325
Adults	0.1	2	16	0	1	420,132
Children	0.0	1	23	0	0	663,025
Unknown	0.2	3	21	0	1	833
Gender						
Female	0.1	2	17	0	1	651,930
Male	0.1	1	19	0	0	535,932
Unknown	0.0	0	0	0	0	0
Race						
White	0.1	2	17	0	1	700,429
African American	0.1	1	14	0	0	13,764
Other/unknown	0.0	1	19	0	0	473,669
Use of Nursing Facil	ities <sup>d</sup>					
Entire year	1.2	17	14	0	5	844
Part year	1.2	42	34	0	4	1,368
None	0.1	2	17	0	1	1,185,650
Maintenance Assista	nce Status					
Cash	0.2	4	17	0	1	213,130
Medically needy	0.1	2	15	0	1	75,110
Poverty related	0.0	1	24	0	0	473,322
Other/unknown	0.1	2	17	0	1	426,300

a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005.

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include they barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

TABLE ND.13 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS  $^{a,b,c}$  VERMONT, 2005

Drug Category	Number of Users	Rx \$ per User	Total Rx \$	Rx \$ as a Percentage of All Part D Excluded Rx \$	Total Number Rx.	\$ per Rx	Number Rx as a Percentage of All Part D Excluded Rx
All	32,146	\$60	\$1,925,964	100.0	109,093	\$18	100.0
Anorexia or weight loss/gain	54	285	15,371	0.8	155	99	0.1
Fertility drugs	5	46	229	0.0	5	46	0.0
Drugs for cosmetic purposes	152	17	2,604	0.1	207	13	0.2
Cough and cold medications	5,402	45	244,771	12.7	8,719	28	8.0
Vitamins and minerals	1,955	57	111,658	5.8	6,058	18	5.6
Non-prescription drugs	14,722	46	679,547	35.3	41,674	16	38.2
Barbiturates	144	52	7,466	0.4	1,191	6	1.1
Benzodiazepines	9,109	74	672,738	34.9	49,000	14	44.9
Other Part D Excl Rx Drugs	603	318	191,580	9.9	2,084	92	1.9

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.13 includes the beneficaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2005. A beneficiary who sused drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

b. Includes OTC drugs as well as prescription drugs.

c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

APPENDIX TABLE A.1 CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY<sup>a, b</sup> NONDLIAL BENEFICIADIES VEDMONT 2005

			Number of			CIARIES, VERMONT	, 2003		Number of B	enefit Mor	nths	
Beneficiary Characteristics	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown
All	126,454	278	9,117	49,443	67,516	100	1,187,862	2,547	101,325	420,132	663,025	833
Age												
5 and younger	22,612	0	351	0	22,261	0	214,363	0	3,869	0	210,494	0
6-14	31,853	1	1,345	1	30,506	0	328,438	12	15,369	5	313,052	0
15-20	17,630	0	1,206	2,078	14,343	3	165,768	0	13,617	15,950	136,186	15
21-44	38,707	0	2,854	35,401	400	52	330,978	0	31,636	295,713	3,221	408
45-64	15,212	3	3,300	11,860	5	44	144,229	36	36,180	107,545	60	408
65-74	221	85	50	85	0	1	2,065	782	522	759	0	2
75-84	127	101	9	16	1	0	1,180	921	108	139	12	0
85 and older	92	88	2	2	0	0	841	796	24	21	0	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Gender												
Female	68,603	160	4,788	30,240	33,315	100	651,930	1,482	53,578	268,496	327,541	833
Male	57,851	118	4,329	19,203	34,201	0	535,932	1,065	47,747	151,636	335,484	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Race												
White	72,333	142	7,025	33,157	31,957	52	700,429	1,290	78,900	289,574	330,240	425
African American	1,474	3	87	633	751	0	13,764	36	948	5,307	7,473	0
Other/unknown	52,647	133	2,005	15,653	34,808	48	473,669	1,221	21,477	125,251	325,312	408
Use of Nursing Facilities <sup>c</sup>												
Entire year	87	33	53	0	0	1	844	302	541	0	0	1
Part year	132	12	101	19	0	0	1,368	133	1,064	171	0	0
None	126,235	233	8,963	49,424	67,516	99	1,185,650	2,112	99,720	419,961	663,025	832
Maintenance Assistance Statu	s											
Cash	20,192	31	7,719	3,990	8,452	0	213,130	341	87,546	39,126	86,117	0
Medically needy	8,588	116	578	5,557	2,337	0	75,110	1,028	5,264	50,340	18,478	0
Poverty related	49,405	0	0	2,532	46,773	100	473,322	0	0	17,874	454,615	833
Other/unknown	48,269	131	820	37,364	9,954	0	426,300	1,178	8,515	312,792	103,815	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	126,454	278	9,117	49,443	67,516	100	1,187,862	2,547	101,325	420,132	663,025	833
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
MC all year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
MC all year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0

a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.
b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories

are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

### APPENDIX TABLE A.2

## MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS<sup>a</sup> NONDUAL BENEFICIARIES, VERMONT, 2005

		aries and				
	Benefit Months in Cell J of Table 1		Included in Cell K of Table 1 E		Excluded from Cell K of Table 1	
	Number of Beneficiaries	Number of Benefit Months	Number of Beneficiaries	Number of Benefit Months		Number of Benefit Months
All	126,454	1,187,862	126,454	1,187,862	0	0
Fee-for-service (FFS) all year	126,454	1,187,862	126,454	1,187,862	0	0
FFS part year, with Rx claims	0	0	0	0	0	0
FFS part year, with no Rx claims	0	0	0	0	0	0
Managed care (MC) all year, with Rx claims	0	0	0	0	0	0
MC all year, with no Rx claims	0	0	0	0	0	0

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.